“When a cancer patient with ascites who are continuously receiving 20% albumin twice a day, which is not subject to reimbursement coverage, for non-reimbursements with patient consent in tertiary hospitals, is transferred to DRG-applied hospital, the secondary hospitals or public hospitals cannot pay the cost even with non-reimbursements payment, so the treatment cannot be continued.” This evidence concerns the gene ALB and cancer.